【一周新资讯--结直肠癌 215】2024 W3501

主要研究结果：

• 共纳入1246例接受癌症相关肝切除的患者：平均年龄63.2岁、39.8%为女性、56.1%为结直肠癌肝转移

• 在麻醉诱导时随机分为氨甲环酸1g推注随后1g输注 8小时组或配对安慰剂组(619/626)

• 两组围手术期特征相似

• 氨甲环酸组与对照组的红细胞输血率分别为16.3%与14.5%(P=0.38)

• 两组间的术中出血量和7天内估计的总出血量相似

• 相比于安慰剂组，氨甲环酸组的并发症更多(OR=1.28；P=0.03)，VTE无显著差异(OR=1.68；P=0.08)

参考文献：

Karanicolas PJ, Lin Y, McCluskey SA, Tarshis J, Thorpe KE, Wei A, Dixon E, Porter G, Chaudhury P, Nanji S, Ruo L, Tsang ME, Skaro A, Eeson G, Cleary S, Moulton CA, Ball CG, Hallet J, Coburn N, Serrano PE, Jayaraman S, Law C, Tandan V, Sapisochin G, Nagorney D, Quan D, Smoot R, Gallinger S, Metrakos P, Reichman TW, Jalink D, Bennett S, Sutherland F, Solano E, Molinari M, Tang ES, Warner SG, Bathe OF, Barkun J, Kendrick ML, Truty M, Roke R, Xu G, Lafreniere-Roula M, Guyatt G; HPB CONCEPT Team. Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial. JAMA. 2024 Aug 19. doi: 10.1001/jama.2024.11783. Epub ahead of print. PMID: 39158894.

主要研究结果：

• 共纳入155例接受HER2靶向治疗的ERBB2扩增实体瘤患者

• ERBB2野生型、未知意义变异和致病变异的ORR分别为50%、51%和35%

• 配对的基因组和转录组数据分析：在11例配对WES和全转录组测序数据集的患者中，发现1例与剪接相关的新变异c.644-66_-2del

• 缺乏帕妥珠单抗的结合域，在进展的转移性肿瘤中作为一种潜在的致病变异

• ctDNA的时间序列分析：c.644-66_-2del是一种获得性变异

参考文献：

Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y. Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clin Cancer Res. 2024 Aug 20:OF1-OF12. doi: 10.1158/1078-0432.CCR-24-1023. Epub ahead of print. PMID: 39163021.

主要研究结果：

• 共纳入102例BRAF突变型mCRC，靶向治疗的类型(抗EGFR药物 vs. 非抗EGFR药物)对结局无显著影响

• 左侧原发肿瘤：抗EGFR单克隆抗体的ORR/PFS/OS均好于非抗EGFR药物

• ORR：58% vs. 34%, P<0.01

• PFS：HR=0.62; 95%CI:0.34-1.13; P=0.12

• OS：HR=0.38; 95%CI:0.20-0.72; P<0.01

• 右侧原发肿瘤：抗EGFR单克隆抗体对ORR无影响，PFS/OS均更差

• ORR：33% vs. 36%, P>0.99

• PFS：HR=1.97; 95%CI:1.12-3.47; P=0.02

• OS：HR=1.76; 95%CI:0.99-3.13; P=0.05

参考文献：

Alig AHS, Modest DP, Stintzing S, Heinrich K, Geissler M, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Held S, Moosmann N, Stahler A, Tannapfel A, Giessen-Jung C, Jung A, Weiss L, Heinemann V. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI. ESMO Open. 2024 Aug 21;9(9):103677. doi: 10.1016/j.esmoop.2024.103677. Epub ahead of print. PMID: 39173562.

主要研究结果：

• 共纳入33例既往接受过至少两次治疗的MSS/RAS WT mCRC